MARKET

ASLN

ASLN

Aslan Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.960
+0.120
+6.52%
After Hours: 1.990 +0.03 +1.53% 18:15 12/04 EST
OPEN
1.840
PREV CLOSE
1.840
HIGH
2.040
LOW
1.840
VOLUME
709.77K
TURNOVER
--
52 WEEK HIGH
2.900
52 WEEK LOW
0.8300
MARKET CAP
62.82M
P/E (TTM)
-1.5385
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
CytoDyn (CYDY) Enrolls First Patient in NASH Study on Leronlimab
CytoDyn (CYDY) enrolls first patient in the phase II study evaluating leronlimab for the treatment of nonalcoholic steatohepatitis.
Zacks · 1d ago
Intellia (NTLA) Catches Eye: Stock Jumps 7.8%
Intellia (NTLA) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
Zacks · 1d ago
Acceleron (XLRN) Gets Orphan Drug Tag for ACE-1334 by FDA
The FDA grants orphan drug designation to Acceleron's (XLRN) ACE-1334 for the treatment of patients with systemic sclerosis.
Zacks · 2d ago
Amicus (FOLD) Initiates Rolling BLA Submission for AT-GAA
Zacks · 2d ago
Verastem (VSTM) Begins Phase II Combo Study for Ovarian Cancer
Verastem (VSTM) initiates phase II registration-directed study of VS-6766 and defactinib in patients with recurrent low-grade serous ovarian cancer.
Zacks · 3d ago
Deciphera (DCPH) Ends Qinlock Second-Line GIST Study Enrollment
Deciphera (DCPH) completes enrollment in the phase III study evaluating Qinlock in patients with second-line gastrointestinal stromal tumor.
Zacks · 3d ago
ORIC Pharmaceuticals (ORIC) in Focus: Stock Moves 6.7% Higher
ORIC Pharmaceuticals (ORIC) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
Zacks · 3d ago
Is ASLAN Pharmaceuticals Limited (ASLN) A Good Stock To Buy?
The Insider Monkey team has completed processing the quarterly 13F filings for the September quarter submitted by the hedge funds and other money managers included in our extensive database. Most hedge fund investors experienced strong gains on the back of a strong market performance, which certainly propelled them to adjust their equity holdings so as […]
Insider Monkey · 5d ago
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ASLN. Analyze the recent business situations of Aslan Pharms through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ASLN stock price target is 5.50 with a high estimate of 6.00 and a low estimate of 5.00.
EPS
Institutional Holdings
Institutions: 16
Institutional Holdings: 3.85M
% Owned: 12.01%
Shares Outstanding: 32.05M
TypeInstitutionsShares
Increased
1
11.69K
New
4
-34.29K
Decreased
2
57.65K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.89%
Pharmaceuticals & Medical Research
+1.72%
Key Executives
Chairman/Director
Andrew Howden
Chief Executive Officer/Director
Carl Firth
Vice President - Finance
Kiran Asarpota
Vice President
Alison Ward
Other
Kenneth Kobayashi
Director
Damien Lim
Director
Jun Wu
Independent Director
Robert Hoffman
Independent Director
Chin-Feng Sun
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About ASLN
ASLAN Pharmaceuticals Limited (ASLAN) is a clinical-stage immunology and oncology-focused biopharmaceutical company. ASLAN has a clinical portfolio comprised of a first in class monoclonal therapy, ASLAN004, that is being developed in atopic dermatitis and other immunology indications, and a small molecule inhibitor targeting oncology.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Aslan Pharmaceuticals Ltd (ADR) stock information, including NASDAQ:ASLN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ASLN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ASLN stock methods without spending real money on the virtual paper trading platform.